- Home
- FLYW vs DYN Comparison
FLYW vs DYN Comparison
Compare FLYW & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYW
- DYN
- Stock Information
- Founded
- FLYW 2009
- DYN 1984
- Country
- FLYW United States
- DYN United States
- Employees
- FLYW N/A
- DYN 192
- Industry
- FLYW Computer Software: Prepackaged Software
- DYN Medicinal Chemicals and Botanical Products
- Sector
- FLYW Technology
- DYN Health Care
- Exchange
- FLYW Nasdaq
- DYN Nasdaq
- Market Cap
- FLYW 1.2B
- DYN 1.2B
- IPO Year
- FLYW 2021
- DYN 2020
- Fundamental
- Price
- FLYW $10.84
- DYN $9.07
- Analyst Decision
- FLYW Buy
- DYN Strong Buy
- Analyst Count
- FLYW 16
- DYN 15
- Target Price
- FLYW $16.21
- DYN $43.07
- AVG Volume (30 Days)
- FLYW 2.4M
- DYN 3.4M
- Earning Date
- FLYW 08-05-2025
- DYN 08-11-2025
- Dividend Yield
- FLYW N/A
- DYN N/A
- EPS Growth
- FLYW N/A
- DYN N/A
- EPS
- FLYW 0.04
- DYN N/A
- Revenue
- FLYW $511,493,000.00
- DYN N/A
- Revenue This Year
- FLYW $18.35
- DYN N/A
- Revenue Next Year
- FLYW $15.17
- DYN N/A
- P/E Ratio
- FLYW $302.67
- DYN N/A
- Revenue Growth
- FLYW 20.97
- DYN N/A
- 52 Week Low
- FLYW $8.20
- DYN $6.36
- 52 Week High
- FLYW $23.40
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- FLYW 42.68
- DYN 45.47
- Support Level
- FLYW $11.04
- DYN $8.25
- Resistance Level
- FLYW $11.43
- DYN $9.83
- Average True Range (ATR)
- FLYW 0.39
- DYN 0.56
- MACD
- FLYW -0.12
- DYN 0.14
- Stochastic Oscillator
- FLYW 10.67
- DYN 74.80
About FLYW Flywire Corporation Voting
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements namely a payments platform; a proprietary global payment network and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.